ARTICLE | Clinical News

Fosbretabulin: Phase II started

September 29, 2014 7:00 AM UTC

OxiGene began an open-label, U.S. Phase II trial to evaluate 60 mg/m 2 IV Zybrestat given on days 1, 8 and 15 of a 3-week cycle for up to 3 cycles or until progression or unacceptable toxicity in about 20 patients. The trial is enrolling adult patients with well-differentiated, low-to-intermediate-grade, unresectable or metastatic GI-NETs with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies. ...